A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

Prior treatment

• Previously received treatment with oncolytic viruses, gene therapy.
• Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of VRT106.

Other illness

• Subject is known to have an allergic reaction to any of the components of VRT106.

Other

• Patients with extracranial metastases.
• Patients who can't have a cranial MRI scan.
• Women who are breastfeeding.

• Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures.
• Males and females are aged at 18-70 years (including borderline values) at the time of signing the ICF, male or female.
• Diagnosed with recurrent/progressive glioblastoma.
• Karnofsky Performance Status (KPS) score ≥60 within 28 days prior to the first administration of the study drug.
• An expected survival time of≥3 months.
• Have sufficient organ function.
• Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to the first use of the study drug (if a false-positive pregnancy test result is due to non-pregnancy factors such as illness, further testing via ultrasound or other methods is required, and the investigator must confirm the absence of pregnancy before enrollment).
• Subjects of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose.